Biogen Inc.
BIIB
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer's disease and launched the first approved tr…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$10.30B
▲ +2.2% YoY
Net Income (TTM)
$348M
▼ -20.8% YoY
Op. Margin
4.32%
▼ -4.0pp YoY
ROIC
1.35%
▼ -1.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$2.07B
▼ -24.7% YoY
Op. Cash Flow (TTM)
$2.25B
▼ -23.3% YoY
Net Debt
$6.10B
Cash & Equiv.
$1.30B
5Y CAGR: -6.0%
5Y CAGR: -11.6%
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with BIIB
Held by ETFs
BIIB is in 307 US ETFs. The largest of them, with BIIB's weight in each:
Biogen (BIIB) in four numbers
Questions about Biogen
Is Biogen (BIIB) overvalued?
At $253.40, Biogen's price is 1243% above the $18.87 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 109.22 times earnings and 18.09 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Biogen's fair value?
Intrinsiqq's calculator puts Biogen's fair value at $18.87 a share. It grows earnings per share 0% a year for 5 years, applies an exit P/E of 13.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $14.15. Every input can be changed on the Intrinsic Value tab.
Is Biogen a high-quality business?
Biogen scores 39 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 8 checks computed from SEC filings. Its best check is cash flow growth at 16.0%, and its weakest is return on capital at 1.4%. The Quality tab shows every check against its target.
Does Biogen (BIIB) pay a dividend?
No. Biogen (BIIB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 26 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 13 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BIIB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BIIB
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.